Navigation Links
MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
Date:10/27/2007

SAN FRANCISCO, October 26, 2007 MedImmune, Inc. today announced it will present three abstracts at the American Academy of Pediatrics (AAP) 2007 National Conference & Exhibition, adding to the companys growing body of research into the prevention of respiratory syncytial virus (RSV), a leading cause of hospitalization among infants.

MedImmune is pleased to present data that provide key insights into how we can optimize the fight against RSV, said Jessie R. Groothuis, M.D., vice president, medical and scientific affairs, infectious disease. Cost-effectiveness data help insurers, governments, and families understand the benefits of RSV prophylaxis and the potential impact of not taking preventive measures. Surveillance data help us understand local variants in RSV outbreaks, which can inform and improve RSV prevention guidelines.

MedImmune abstracts to be presented at AAP include:

  • Cost-Effectiveness of Respiratory Syncytial Virus Prophylaxis with Palivizumab Among Preterm Infants After Valuing a Reduction in Persistent Wheezing (Poster #P14) Mark J. Polak, M.D., Saturday, October 27th, 2007 from 12:15 1:00 p.m.

    BACKGROUND: Recent trials have suggested that Synagis (palivizumab), a monoclonal antibody (MAb) that is the standard of care in RSV prevention, reduced the incidence of persistent wheezing in studied populations. Researchers conducted a cost-effectiveness analysis of prophylaxis with Synagis compared with no prophylaxis among preterm infants less than 32 weeks and between 32 and 35 weeks gestation, factoring in the quality of life associated with a reduction in persistent wheezing.

  • A Nationwide Hospital RSV Surveillance Program: Interim Assessment of the 2006-2007 RSV Season (Poster #P25) Marnie L. Boron, PharmD, Saturday, October 27th, 2007 from 12:15 1:00 p.m.

    BACKGROUND: Due to limited uniformity in RSV testing and local surveillance reporting, nationwide RSV prevent
    '/>"/>


Contact: Tor Constantino
301-398-5801
Edelman Public Relations
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent Pharma Solutions, the ... and consumer health products, today welcomed the announcement by OPKO Health that the ... for a new treatment for chronic kidney disease (CKD) and vitamin D insufficiency, ...
(Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... ... services to help patients in need. Most people know that general health emergencies, such ... Unfortunately, a fewer amount of people know where to turn to during a dental ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, Inc. today launched the ... as well as announced the date of its next major release. , Version ... management tasks as well as enhancements to the customer experience. Users now ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... Physician Leadership ® and Navigant Center for Healthcare Research and Policy Analysis show ... Fifty-five percent of respondents said they agreed or strongly agreed that the controversial ...
(Date:8/3/2015)... NJ (PRWEB) , ... August 03, 2015 , ... ... to announce the development of it’s new program “Designing Secure Healthcare Systems” ... architects, engineers and technology leaders from healthcare organizations with access to the tactics, ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Novatus Unveils Milestone Software Release 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4
... YORK, April 28 Crystal Research Associates, LLC,announced ... Overview(R),(EIO(R)) on BioCurex Inc. (OTC Bulletin Board: BOCX). ... http://www.crystalra.com ., BioCurex, Inc. ("BioCurex" or "the ... diagnosis, imaging, and therapy that target,a global oncology ...
... Establishes Effects of Puzzle ... and Word Games on the Human Body and Mind, ... Carolina,University,s Department of Recreation and Leisure Studies today revealed,the ... measured,the stress-relieving and other mood-lifting effects of so-called "casual",video ...
... drug developed to relieve one of the major side ... approval from the United States Food and Drug Administration ... of opioid-induced bowel disorders in patients receiving palliative care ... FDA,s European equivalent, the Committee for Medicinal Products for ...
... Sylvie Bouchard to Retire from Company -, ... (TSX: DDS;,NASDAQ: DDSS) today announced that Claire Brulle, ... Officer of the Company. Incumbent,Chief Medical Officer Dr. ... on her career practicing medicine., "Dr. Brulle ...
... Available at 1,440 Stores in May 2008, ... Ltd., a medical,device company publicly traded on the ... its RESPeRATE(R) hypertension treatment device,clinically-proven to significantly lower ... the United Kingdom this May through,Lloyds Pharmacy, the ...
... TORONTO, April 28 Readers in Europe and other ... Story, the debut book,from London-born author Shireen Jeejeebhoy. It ... who made medical history as the first,person to live ... The book has just scooped awards in the US ...
Cached Medicine News:Health News:Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BioCurex, Inc. 2Health News:Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BioCurex, Inc. 3Health News:Study: Casual Video Games Demonstrate Ability to Relieve Stress, Improve Mood: Potential Clinical Significance Highlighted 2Health News:Study: Casual Video Games Demonstrate Ability to Relieve Stress, Improve Mood: Potential Clinical Significance Highlighted 3Health News:Study: Casual Video Games Demonstrate Ability to Relieve Stress, Improve Mood: Potential Clinical Significance Highlighted 4Health News:Study: Casual Video Games Demonstrate Ability to Relieve Stress, Improve Mood: Potential Clinical Significance Highlighted 5Health News:Study: Casual Video Games Demonstrate Ability to Relieve Stress, Improve Mood: Potential Clinical Significance Highlighted 6Health News:Study: Casual Video Games Demonstrate Ability to Relieve Stress, Improve Mood: Potential Clinical Significance Highlighted 7Health News:Drug developed at the University of Chicago wins FDA approval 2Health News:Drug developed at the University of Chicago wins FDA approval 3Health News:Drug developed at the University of Chicago wins FDA approval 4Health News:Labopharm Appoints Dr. Claire Brulle as Senior Vice-President and Chief Medical Officer 2Health News:InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group 2Health News:InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group 3Health News:InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group 4Health News:Story of Woman's Courage and Medical Innovation Top Choice for Readers 2
(Date:8/3/2015)... -- Biosensors International Group, Ltd. ("Biosensors" or the ... a developer, manufacturer and marketer of innovative medical ... fiscal quarter ended 30 June 2015 ("Q1 FY16"). ... , Biosensors continued to make ... by lower operating expenses and operational improvement. Operating ...
(Date:8/3/2015)... 2015 /OFF HOLD OFF ... PIV757417 The following release: "Biotech Advancements Coupled with ... & Treatments for Critical-Care Patients With Severe Wound ... Aug 2015 12:30 GMT Cooperative research ... research and top-tier universities for identifying biotech solutions ...
(Date:8/3/2015)... BioPharma Inc. (NASDAQ: ARRY ) today reported ... of its fiscal year ended June 30, 2015. ... noted, "Binimetinib and encorafenib, two innovative oncology products ... submissions in 2016. Additional data shared over the ... further validate the value of these programs by ...
Breaking Medicine Technology:Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12
... (Nasdaq: ARNA ) today announced positive preliminary ... in patients with chronic insomnia. APD125,is an orally ... being,evaluated in insomnia patients who have difficulty maintaining ... patients treated with APD125,experienced statistically significant improvements in ...
... N.J., Sept. 25 DOV Pharmaceutical,Inc. ("DOV", or ... additional Phase Ib results for DOV 21,947, its ... depression and obesity. A,preliminary analysis of the study ... at the doses examined, and produced a statistically,significant ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 2Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 3Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 4Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 5Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 6Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 7DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study 2DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study 3DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study 4DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study 5
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
... HumaPen MEMOIR is the first and only insulin pen ... and amount of your last 16 doses (including priming ... insulin you last took. With HumaPen MEMOIR, you simply ... one-unit increments (up to 60 units) after initial set-up. ...
PulmoLife is a new COPD screening device, designed for quick and easy screening of adult smokers for early detection of COPD....
Medicine Products: